Skip to Content

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Next-Generation CyTOF XT Redefines Cytometry with Advances in Automation, Throughput, Time to Results and Total Cost of Ownership
A New Platform to Simplify Deep Profiling of the Human Immune System SOUTH SAN FRANCISCO, Calif. , May 25, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced the
View HTML
Toggle Summary Imaging Mass Cytometry Utilized by Global Consortium Focused on New Precision Medicine Approaches for Treatment of Rheumatoid Arthritis
FLAMIN-GO Project Seeks to Develop Organ-on-a-Chip Technology for Clinical Trials in Rheumatoid Arthritis Therapy SOUTH SAN FRANCISCO, Calif. , May 24, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through
View HTML
Toggle Summary Fluidigm to Present at Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif. , May 14, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, announced today that the company’s management will participate in several upcoming
View HTML
Toggle Summary Fluidigm Announces Virtual Mass Cytometry Webinar Investor Event on May 24, 2021, at 1:00 p.m. Eastern Time
SOUTH SAN FRANCISCO, Calif. , May 10, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that it will host a virtual investor event that will showcase competitive
View HTML
Toggle Summary Fluidigm Announces First Quarter 2021 Financial Results with Total Revenue of $32.8 Million, Up 19 Percent Over Prior Year Period
Forecasting underlying base business growth of 16–17% supported by new product innovation SOUTH SAN FRANCISCO, Calif. , May 06, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight,
View HTML
Toggle Summary Data Published in Nature Communications Demonstrate the Power of Fluidigm’s CyTOF and Imaging Mass Cytometry Technologies to Transform Cancer Drug Discovery and Enable New Precision Medicine Approaches in Clinical Oncology
Study Suggests Mass Cytometry Is a Valuable Tool for Predicting Individual Patient Response to Therapies SOUTH SAN FRANCISCO, Calif. , May 06, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive
View HTML
Toggle Summary Fluidigm Announces Conference Call and Webcast of First Quarter 2021 Financial Results
SOUTH SAN FRANCISCO, Calif. , April 08, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation  (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that it will report first quarter 2021 financial results on Thursday,
View HTML
Toggle Summary FDA Grants Emergency Use Authorization for Home Collection Kit for Advanta Dx SARS-CoV-2 RT-PCR Assay
Collaboration Agreement to Market AZOVA COVID-19 Test Collection Kit Online AZOVA Digital Health Platform Provides Patient Questionnaire, Process for Prescription, Kit Purchase , Sample Collection, and Secure Delivery of Test Results SOUTH SAN FRANCISCO, Calif.
View HTML
Toggle Summary Fluidigm Announces Fourth Quarter and Full Year 2020 Financial Results
Fourth Quarter Total Revenue Increased 38 Percent to $44.6 million Fourth Quarter Product and Service Revenue Increased 26 Percent to $40.5 million Full Year Total Revenue Increased 18 Percent to $138.1 million Collaboration with PLT Tech to Market CyTOF Technology to Clinical Labs in China SOUTH
View HTML
Toggle Summary George Mason University Providing COVID-19 Testing with Saliva-Based Advanta Dx SARS-CoV-2 RT-PCR Assay on Biomark HD Platform
SOUTH SAN FRANCISCO, Calif. , Feb. 10, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation  (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that George Mason University in Fairfax, Va.
View HTML